AGIO PDUFA decision: Sunday, November 1, 2026

…ative prescriptions written as of June 30, 2026 • sNDA for mitapivat granted FDA Priority Review in sickle cell disease with PDUFA goal date of November 1, 2026 • Diversified and expanded late-stage pipeline with licensing of cevidoplenib for immune thrombocytopenia and advancement of A

Dates are sourced from official registries and filings and can change — estimated dates (marked ~) slip routinely. This page updates automatically when the source registry moves the date. Research information only, not investment advice.